Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TOP1 | P11387 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10886696 | 0.98 | EP300 (0.45) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL10893304 | 0.98 | EP300 (0.45) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL10531391 | 0.98 | EP300 (0.45) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL798325 | 0.93 | — | — | |
| SCHEMBL998029 | 0.83 | — | — | |
| SCHEMBL204638 | 0.82 | TSHR (0.41) | TSHRMAPTFAAHMAPK1 | |
| SCHEMBL798306 | 0.82 | CNR1 (0.33) | CYP1A2MAPTCYP2C19CYP2C9TP53 | |
| SCHEMBL1556892 | 0.80 | PPARG (0.42) | EP300PPARGPPARA | |
| SCHEMBL9800734 | 0.80 | EP300 (0.50) | EP300TSHRTERTPTPN1PPARG | |
| SCHEMBL1415923 | 0.80 | FAAH (0.48) | EP300TERTPTPN1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256471-B1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-12-12 | — | — | EP | claimed |
| US-10093671-B2 | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-10-09 | — | — | US | claimed |
| EP-3256471-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | claimed |
| US-20170342069-A1 | NOVEL 2-OXO-6, 7-DIHYDROBENZO[a]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-11-30 | — | — | US | claimed |
| WO-2016128335-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | claimed |
| US-4315855-A | Monoazo disperse dyes containing a nitrophenyl group and a homophthalimide group | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | claimed |
| EP-3256471-B1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-10093671-B2 | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3256471-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-20170342069-A1 | NOVEL 2-OXO-6, 7-DIHYDROBENZO[a]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2017-11-30 | — | — | US | disclosed |
| WO-2016128335-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | JAPAN TOBACCO INC. | 2005-02-10 | — | — | US | disclosed |
| US-20050032748-A1 | Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease | CELL THERAPEUTICS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6774130-B2 | TREATING CHRONIC INFLAMMATORY DISEASE, CHRONIC INTESTINAL INFLAMMATION, ARTHRITIS, PSORIASIS, ASTHMA AND AUTOIMMUNE DISORDERS; TH1 CELL-MEDIATED DISORDERS; FOR EXAMPLE, 1,2,3,6-TETRAHYDRO-7H-PURINE-2,6-DIONE DERIVATIVES | CELL THERAPEUTICS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CELL THERAPEUTICS, INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| US-4315855-A | Monoazo disperse dyes containing a nitrophenyl group and a homophthalimide group | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | EP300 4422/4885TSHR 3418/4885TERT 3603/4885 |
| US-20170342069-A1 | NOVEL 2-OXO-6, 7-DIHYDROBENZO[a]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2B6, CYP2A6 | EP300 2258/4885TSHR 1738/4885TERT 2809/4885 |
| US-20050032748-A1 | Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease | TPMT, IL2, NFATC1 | EP300 4643/4885TSHR 1195/4885TERT 3012/4885 |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CCR10, IL1RN, CCR1 | EP300 4842/4885TSHR 1152/4885TERT 4181/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | EP300 1799/4885TSHR 192/4885TERT 4074/4885 |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | CASR, CALCR, GRK2 | EP300 1624/4885TSHR 368/4885TERT 4205/4885 |
| US-10093671-B2 | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, CYP2B6, CYP2A6 | EP300 2148/4885TSHR 2057/4885TERT 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.